Trial Outcomes & Findings for Lifting and Tightening of the Face in Subjects With Skin of Darker Color (NCT NCT01368965)

NCT ID: NCT01368965

Last Updated: 2017-12-13

Results Overview

The percentage of participants assessed to have improvement in skin laxity, i.e., lifted and tightened skin in the areas treated with the Ulthera System, as determined by three masked assessors comparing pre-treatment and 90-days post-treatment photos

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

54 participants

Primary outcome timeframe

90 days post treatment

Results posted on

2017-12-13

Participant Flow

Subjects desiring lift/tightening of cheek tissue, or improved jawline definition and/or submental skin laxity, and were Fitzpatrick skin types 3-6 were recruited. Fifty-four subjects were enrolled at two facilities. Study recruitment initiated 2/16/11; follow-up concluded 1/18/12.

Fifty-four subjects who met study eligibility requirements were assigned a study subject ID. Two subjects withdrew from the study due prior to study treatment. Data from these subjects are not included in the demographic summaries or in the efficacy analyses. Fifty-two subjects received study treatment.

Participant milestones

Participant milestones
Measure
Treated Subjects
All treated study subjects received a full face Ulthera® treatment.
Overall Study
STARTED
52
Overall Study
Subject Withdrawal Prior to Treatment
2
Overall Study
COMPLETED
40
Overall Study
NOT COMPLETED
12

Reasons for withdrawal

Reasons for withdrawal
Measure
Treated Subjects
All treated study subjects received a full face Ulthera® treatment.
Overall Study
Lost to Follow-up
12

Baseline Characteristics

Lifting and Tightening of the Face in Subjects With Skin of Darker Color

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Treated Subjects
n=52 Participants
Study subjects who received a full face Ulthera treatment. (n=52)
Age, Continuous
53 years
n=5 Participants
Sex: Female, Male
Female
51 Participants
n=5 Participants
Sex: Female, Male
Male
1 Participants
n=5 Participants
Race/Ethnicity, Customized
African American/Black
35 participants
n=5 Participants
Race/Ethnicity, Customized
Hispanic/Latino
5 participants
n=5 Participants
Race/Ethnicity, Customized
Asian
10 participants
n=5 Participants
Race/Ethnicity, Customized
Other
2 participants
n=5 Participants
Region of Enrollment
United States
52 participants
n=5 Participants
Fitzpatrick Skin Type
Type III
9 participants
n=5 Participants
Fitzpatrick Skin Type
Type IV
25 participants
n=5 Participants
Fitzpatrick Skin Type
Type V
15 participants
n=5 Participants
Fitzpatrick Skin Type
Type VI
3 participants
n=5 Participants

PRIMARY outcome

Timeframe: 90 days post treatment

Population: Masked, qualitative assessment of standardized photographs at 90 days post treatment compared to baseline, could not be completed as images taken at one site were not recovered due to poor data management and staffing issues at the site.

The percentage of participants assessed to have improvement in skin laxity, i.e., lifted and tightened skin in the areas treated with the Ulthera System, as determined by three masked assessors comparing pre-treatment and 90-days post-treatment photos

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 90 Days post-treatment

Population: The GAIS is 5-point scale (1-5) describing an overall assessment as follows: 1. = Very Much Improved 2. = Much Improved 3. = Improved 4. = No Change 5. = Worse

At 90 days post-treatment, each site investigator and each subject completed a Global Aesthetic Improvement Scale (GAIS), comparing with pre-treatment photos. PGAIS = Physician Global Aesthetic Improvement Scale; SGAIS = Subject Global Aesthetic Improvement Scale.

Outcome measures

Outcome measures
Measure
Treated Subjects
n=48 Participants
All treated study subjects received a full face Ulthera® treatment.
Global Aesthetic Improvement at 90 Days Post-treatment
PGAIS - Improved to Very Much Improved
85.4 percentage of participants improved
Global Aesthetic Improvement at 90 Days Post-treatment
SGAIS - Improved to Very Much Improved
79.2 percentage of participants improved

SECONDARY outcome

Timeframe: 180 days post-treatment

Population: Subjects completing the 180-Day SGAIS = 39; however, the 180-Day PGAIS was not obtained for 2 subjects. PGAIS data are based on n=37. The GAIS is 5-point scale (1-5) describing an overall assessment as follows: 1. = Very Much Improved 2. = Much Improved 3. = Improved 4. = No Change 5. = Worse

At 180 days post-treatment, each site investigator and each subject completed a Global Aesthetic Improvement Scale (GAIS), comparing with pre-treatment photos. PGAIS = Physician Global Aesthetic Improvement Scale; SGAIS = Subject Global Aesthetic Improvement Scale.

Outcome measures

Outcome measures
Measure
Treated Subjects
n=39 Participants
All treated study subjects received a full face Ulthera® treatment.
Global Aesthetic Improvement at 180 Days Post-treatment
PGAIS - Improved to Very Much Improved
54.0 percentage of participants improved
Global Aesthetic Improvement at 180 Days Post-treatment
SGAIS - Improved to Very Much Improved
77.0 percentage of participants improved

SECONDARY outcome

Timeframe: 90 Days post-treatment

Population: Data analyzed includes PSQ responses at 90 days post-treatment assessing subjects' satisfaction with study treatment. Responses were tabulated. Outcomes reported represent the percentage of subjects reporting any satisfaction, i.e., Very Satisfied and Satisfied.

Subjects indicated whether they saw improvement, i.e., providing a Yes/No response, in face and neck characteristics at three months (D90) post Ulthera treatment. Pre-treatment and Day 90 post-treatment photographs were available for viewing during the assessment. Subjects also had a mirror in hand for real time assessment. Subjects' Yes/No responses were tabulated.

Outcome measures

Outcome measures
Measure
Treated Subjects
n=47 Participants
All treated study subjects received a full face Ulthera® treatment.
Patient Satisfaction Questionnaire
83.0 percentage of participants Satisfied

SECONDARY outcome

Timeframe: 180 days post-treatment

Population: Data analyzed includes PSQ responses at 180 days post-treatment assessing subjects' satisfaction with study treatment. Responses were tabulated. Outcomes reported represent the percentage of subjects reporting any satisfaction, i.e., Very Satisfied and Satisfied.

Subjects indicated whether they saw improvement, i.e., providing a Yes/No response, in face and neck characteristics at six months (D180) post Ulthera treatment. Pre-treatment and Day 180 post-treatment photographs were available for viewing during the assessment. Subjects also had a mirror in hand for real time assessment. Subjects' Yes/No responses were tabulated.

Outcome measures

Outcome measures
Measure
Treated Subjects
n=40 Participants
All treated study subjects received a full face Ulthera® treatment.
Patient Satisfaction Questionnaire
72.5 percentage of participants Satisfied

OTHER_PRE_SPECIFIED outcome

Timeframe: During Ulthera treatment

Subject assessment of pain using a validated Numeric Rating Scale (NRS), 0-10, where 0 = no pain and 10=worse pain possible. Subjects' sensory responses to the treatment exposures were recorded using the NRS for each anatomical region.

Outcome measures

Outcome measures
Measure
Treated Subjects
n=52 Participants
All treated study subjects received a full face Ulthera® treatment.
Subject Assessment of Pain
Submental Region
6 Average NRS score
Interval 2.0 to 10.0
Subject Assessment of Pain
Submandibular Region
6 Average NRS score
Interval 2.0 to 10.0
Subject Assessment of Pain
Cheek Region
6 Average NRS score
Interval 1.0 to 10.0

Adverse Events

Enrolled Subjects

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Public Disclosure Manager

Merz Pharmaceuticals

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place